EMA commits to safeguarding stakeholder data; FDA advisory panel expands compounding peptide list

The European Medicines Agency announced that it will assume ultimate responsibility for protecting information submitted by stakeholders through online meeting registrations and surveys, in line with EU data‑protection rules.

The agency cited the 2018 EU regulation (EU 2018/1725) that governs how EU institutions must manage personal data, emphasizing its duty to secure registration forms and survey responses from misuse.

In the United States, an FDA advisory committee concluded its two‑day meeting by voting to add six of seven reviewed peptides to the list of bulk drug substances allowed for pharmacy compounding, while rejecting one peptide from the list.